Neuropeptides: Keeping the balance between pathogen immunity and immune tolerance

Current Opinion in Pharmacology

Volumn 10, Issue 4, 2010, Pages 473-481

  Gonzalez Rey, Elena ^a   Ganea, Doina ^b   Delgado, Mario ^a  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; ALPHA INTERMEDIN; ATRIAL NATRIURETIC FACTOR; BRADYKININ; CALCITONIN GENE RELATED PEPTIDE; CHOLECYSTOKININ; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CORTISTATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GALANIN; GHRELIN; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; MELANIN CONCENTRATING HORMONE; NEUROKININ; NEUROPEPTIDE; NEUROPEPTIDE Y; NOCICEPTIN; OPIATE PEPTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SOMATOSTATIN; SUBSTANCE P; TRANSCRIPTION FACTOR FOXP3; UROCORTIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

ALLERGIC ENCEPHALOMYELITIS; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ASTHMA; AUTOIMMUNE DISEASE; BRAIN INJURY; CD4+ CD25+ T LYMPHOCYTE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLITIS; CROHN DISEASE; CYTOKINE PRODUCTION; DEGENERATIVE DISEASE; DOWN REGULATION; DRUG ACTIVITY; DRUG POTENCY; ENDOTOXEMIA; ENTERITIS; FATTY ACID METABOLISM; GENETIC REGULATION; GINGIVITIS; GLUCOSE METABOLISM; HEPATITIS; HUMAN; HYDROPHOBICITY; IMMUNE SYSTEM; IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIA; MACROPHAGE; MICROGLIA; MOUTH INFLAMMATION; NEPHRITIS; NONHUMAN; OSTEOARTHRITIS; PANCREATITIS; PNEUMONIA; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; THYMUS; UVEORETINITIS;

ANTI-INFECTIVE AGENTS; AUTOIMMUNITY; BACTERIAL INFECTIONS; DISEASE SUSCEPTIBILITY; HUMANS; IMMUNE SYSTEM; IMMUNE SYSTEM DISEASES; IMMUNE TOLERANCE; INFLAMMATION; MYCOSES; NEUROIMMUNOMODULATION; NEUROPEPTIDES; PARASITIC DISEASES;

EID: 77955272722     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2010.03.003     Document Type: Review

References (54)

1. Sternberg E.M. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat Rev Immunol 2006, 6:318-328.
2. Gonzalez-Rey E., Delgado M. Anti-inflammatory neuropeptide receptors: new therapeutic targets for immune disorders?. Trends Pharmacol Sci 2007, 28:482-491.
3. Gonzalez-Rey E., Chorny A., Delgado M. Regulation of immune tolerance by anti-inflammatory neuropeptides. Nat Rev Immunol 2007, 7:52-63.
4. Lühder F., Lee D.H., Gold R., Stegbauer J., Linker R.A. Small but powerful: short peptide hormones and their role in autoimmune inflammation. J Neuroimmunol 2009, 217:1-7.
5. Delgado M., Ganea D. Anti-inflammatory neuropeptides: a new class of endogenous immunoregulatory agents. Brain Behav Immun 2008, 22:1146-1151.
6. Brain S.D., Cox H.M. Neuropeptides and their receptors: innovative science providing novel therapeutic targets. Br J Pharmacol 2006, 147:S202-S211.
7. Dello Russo C., Lisi L., Navarra P., Tringali G. Diverging effects of cortistatin and somatostatin on the production and release of prostanoids from rat cortical microglia and astrocytes. J Neuroimmunol 2009, 213:78-83.
8. Gonzalez-Rey E., Delgado M. Vasoactive intestinal peptide inhibits cyclooxygenase-2 expression in activated macrophages, microglia, and dendritic cells. Brain Behav Immun 2008, 22:35-41.
9. Moon M., Kim H.G., Hwang L., Seo J.H., Kim S., Hwang S., Kim S., Lee D., Chung H., Oh M.S., et al. Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation. Neurotox Res 2009, 15:332-347.
10. Delgado M., Varela N., Gonzalez-Rey E. Vasoactive intestinal peptide protects against beta-amyloid-induced neurodegeneration by inhibiting microglia activation at multiple levels. Glia 2008, 56:1091-1103.
11. Bulgarelli I., Tamiazzo L., Bresciani E., Rapetti D., Caporali S., Lattuada D., Locatelli V., Torsello A. Desacyl-ghrelin and synthetic GH-secretagogues modulate the production of inflammatory cytokines in mouse microglia cells stimulated by beta-amyloid fibrils. J Neurosci Res 2009, 87:2718-2727.
12. Delgado M., Ganea D. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. FASEB J 2003, 17:944-946.
13. Theil M.M., Miyake S., Mizuno M., Tomi C., Croxford J.L., Hosoda H., Theil J., von Hörsten S., Yokote H., Chiba A., et al. Suppression of experimental autoimmune encephalomyelitis by ghrelin. J Immunol 2009, 183:2859-2866.
14. Chorny A., Anderson P., Gonzalez-Rey E., Delgado M. Ghrelin protects against experimental sepsis by inhibiting high-mobility group box 1 release and by killing bacteria. J Immunol 2008, 180:8369-8377.
15. Wu R., Dong W., Qiang X., Wang H., Blau S.A., Ravikumar T.S., Wang P. Orexigenic hormone ghrelin ameliorates gut barrier dysfunction in sepsis in rats. Crit Care Med 2009, 37:2421-2426.
16. Tang Y., Lv B., Wang H., Xiao X., Zuo X. PACAP inhibit the release and cytokine activity of HMGB1 and improve the survival during lethal endotoxemia. Int Immunopharmacol 2008, 8:1646-1651.
17. Chorny A., Delgado M. Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1. Am J Pathol 2008, 172:1297-1307.
18. Fink M.P. Neuropeptide modulators of high mobility group box 1 secretion as potential therapeutic agents for severe sepsis. Am J Pathol 2008, 172:1171-1173.
19. Miksa M., Wu R., Cui X., Dong W., Das P., Simms H.H., Ravikumar T.S., Wang P. Vasoactive hormone adrenomedullin and its binding protein: anti-inflammatory effects by up-regulating peroxisome proliferator-activated receptor-gamma. J Immunol 2007, 179:6263-6272.
20. Demers A., Caron V., Rodrigue-Way A., Wahli W., Ong H., Tremblay A. A concerted kinase interplay identifies PPARgamma as a molecular target of ghrelin signaling in macrophages. PLoS One 2009, 4:e7728.
21. George J. Mechanisms of disease: the evolving role of regulatory T cells in atherosclerosis. Nat Clin Pract Cardiovasc Med 2008, 5:531-540.
22. Gonzalez-Rey E., Chorny A., Varela N., O'Valle F., Delgado M. Therapeutic effect of urocortin on collagen-induced arthritis by downregulating inflammatory and Th1 response and inducing regulatory T cells. Arthritis Rheum 2007, 56:531-543.
23. Taylor A.W., Kitaichi N. The diminishment of experimental autoimmune encephalomyelitis (EAE) by neuropeptide alpha-melanocyte stimulating hormone (alpha-MSH) therapy. Brain Behav Immun 2008, 22:639-646.
24. Gonzalez-Rey E., Chorny A., O'Valle F., Delgado M. Adrenomedullin protects from experimental arthritis by downregulating inflammation and Th1 response and inducing regulatory T cells. Am J Pathol 2007, 170:263-271.
25. Gonzalez-Rey E., Delgado M. Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis. Trends Mol Med 2007, 13:241-251.
26. Shevach E.M. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009, 30:636-645.
27. Delgado M. Generating tolerogenic dendritic cells with neuropeptides. Hum Immunol 2009, 70:300-307.
28. Riley J.L., June C.H., Blazar B.R. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity 2009, 30:656-665.
29. Gonzalez-Rey E., Chorny A., Fernandez-Martin A., Ganea D., Delgado M. Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells. Blood 2006, 107:3632-3638.
30. Pozo D., Anderson P., Gonzalez-Rey E. Induction of alloantigen-specific human T regulatory cells by vasoactive intestinal peptide. J Immunol 2009, 183:4346-4359.
31. Anderson P., Gonzalez-Rey E. Vasoactive intestinal peptide induces cell cycle arrest and regulatory functions in human T cells at multiple levels. Mol Cell Biol 2010, 30:2537-2551.
32. Anderson P., Delgado M. Endogenous anti-inflammatory neuropeptides and pro-resolving lipid mediators: a new therapeutic approach for immune disorders. J Cell Mol Med 2008, 2:1830-1847.
33. Kodama T., Ashitani J., Matsumoto N., Kangawa K., Nakazato M. Ghrelin treatment suppresses neutrophil-dominant inflammation in airways of patients with chronic respiratory infection. Pulm Pharmacol Ther 2008, 21:774-779.
34. Prasse A, Zissel G, Lutzen N, Schupp J, Schmiedlin R, Gonzalez-Rey E, Rensing-Ehl A, Bacher G, Cavalli V, Bevec D, et al.: Inhaled vasoactive intestinal peptide exerts immuno-regulatory effects in sarcoidosis. Am J Respir Crit Care Med (in press).
35. Chapter M.C., White C.M., DeRidder A., Chadwick W., Martin B., Maudsley S. Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies. Pharmacol Ther 2010, 125:39-54.
36. Misaka S., Aoki Y., Karaki S., Kuwahara A., Mizumoto T., Onoue S., Yamada S. Inhalable powder formulation of a stabilized vasoactive intestinal peptide (VIP) derivative: anti-inflammatory effect in experimental asthmatic rats. Peptides 2010, 31:72-78.
37. Onoue S., Misaka S., Ohmori Y., Sato H., Mizumoto T., Hirose M., Iwasa S., Yajima T., Yamada S. Physicochemical and pharmacological characterization of novel vasoactive intestinal peptide derivatives with improved stability. Eur J Pharm Biopharm 2009, 73:95-101.
38. Camelo S., Lajavardi L., Bochot A., Goldenberg B., Naud M.C., Brunel N., Lescure B., Klein C., Fattal E., Behar-Cohen F., de Kozak Y. Protective effect of intravitreal injection of vasoactive intestinal peptide-loaded liposomes on experimental autoimmune uveoretinitis. J Ocul Pharmacol Ther 2009, 25:9-21.
39. Fernandez-Montesinos R., Castillo P.M., Klippstein R., Gonzalez-Rey E., Mejias J.A., Zaderenko A.P., Pozo D. Chemical synthesis and characterization of silver-protected vasoactive intestinal peptide nanoparticles. Nanomedicine 2009, 4:919-930.
40. Delgado M., Toscano M.G., Benabdellah K., Cobo M., O'Valle F., Gonzalez-Rey E., Martín F. In vivo delivery of lentiviral vectors expressing vasoactive intestinal peptide complementary DNA as gene therapy for collagen-induced arthritis. Arthritis Rheum 2008, 58:1026-1037.
41. Toscano M.G., Delgado M., Kong W., Martin F., Skarica M., Ganea D. Dendritic cells transduced with lentiviral vectors expressing VIP differentiate into VIP-secreting tolerogenic-like DCs. Mol Ther 2010, 18:1035-1045.
42. Han D., Tian Y., Zhang M., Zhou Z., Lu J. Prevention and treatment of experimental autoimmune encephalomyelitis with recombinant adeno-associated virus-mediated alpha-melanocyte-stimulating hormone-transduced PLP139-151-specific T cells. Gene Ther 2007, 14:383-395.
43. Brod S.A., Hood Z.M. Ingested (oral) alpha-MSH inhibits acute EAE. J Neuroimmunol 2008, 193:106-112.
44. El Karim I.A., Linden G.J., Orr D.F., Lundy F.T. Antimicrobial activity of neuropeptides against a range of micro-organisms from skin, oral, respiratory and gastrointestinal tract sites. J Neuroimmunol 2008, 200:11-16.
45. Charnley M., Moir A.J.G., Douglas C.W.I., Haycock J.W. Anti-microbial action of melanocortin peptides and identification of a novel X-Pro-D/L-Val sequence in gram-positive and gram-negative bacteria. Peptides 2008, 29:1004-1009.
46. Madhuri, Shireen T., Venugopal S.K., Ghosh D., Gadepalli R., Dhawan B., Mukhopadhyay K. In vitro antimicrobial activity of alpha-melanocyte stimulating hormone against major human pathogen Staphylococcus aureus. Peptides 2009, 30:1627-1635.
47. Rauch I., Holzmeister S., Kofler B. Anti-Candida activity of alpha-melanocyte-stimulating hormone (alpha-MSH) peptides. J Leukoc Biol 2009, 85:371-372.
48. Delgado M., Anderson P., Garcia-Salcedo J.A., Caro M., Gonzalez-Rey E. Neuropeptides kill African trypanosomes by targeting intracellular compartments and inducing autophagic-like cell death. Cell Death Differ 2009, 16:406-416.
49. Campos-Salinas J., Gonzalez-Rey E. Autophagy and neuropeptides at the crossroad for parasites: to survive or to die?. Autophagy 2009, 5:551-554.
50. Tan Y.V., Abad C., Lopez R., Dong H., Liu S., Lee A., Gomariz R.P., Leceta J., Waschek J.A. Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2009, 106:2012-2017.
51. Sun W., Hong J., Zang Y.C., Liu X., Zhang J.Z. Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis. Int Immunol 2006, 18:1691-1700.
52. Delgado M., Robledo G., Rueda B., Varela N., O'Valle F., Hernandez-Cortes P., Caro M., Orozco G., Gonzalez-Rey E., Martin J. Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells. Arthritis Rheum 2008, 58:1010-1019.
53. Juarranz Y., Gutierrez-Canas I., Santiago B., Carrion M., Pablos J.L., Gomariz R.P. Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts. Arthritis Rheum 2008, 58:1086-1095.
54. Paladini F., Cocco E., Cauli A., Cascino I., Vacca A., Belfiore F., Fiorillo M.T., Mathieu A., Sorrentino R. A functional polymorphism of the vasoactive intestinal peptide receptor 1 gene correlates with the presence of HLA-B*2705 in Sardinia. Genes Immun 2008, 9:659-667.